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Abstract 15 
Three-layer thin films comprising of two polymers as substrate (ethyl cellulose and, 16 
copovidone K28) and three antihypertensive agents (hydrochlorothiazide, amiloride HCl and 17 
carvedilol) were printed using jet-dispensing technology. Two film formulations with different 18 
ethyl cellulose to copovidone K28 ratio (i.e. 90/10 and 50/50 w/w) were prepared using a three-19 
course dispensing. The films were characterized regarding surface morphology, solid-state 20 
properties, polymer-drug interactions, drug distribution in each layer and their in-vitro drug 21 
release. All the components of the films were found to be in the amorphous state apart from 22 
hydrochlorothiazide which retained its crystallinity. FT-IR spectroscopy revealed hydrogen 23 
bond interactions between carvedilol and copovidone K28. Combinations of ethyl cellulose 24 
and copovidone K28 provide suitable polymeric film substrates with the ability to modify drug 25 
release. Particularly, decreased ethyl cellulose to copovidone K28 weight ratio was found to 26 
suppress the crystallization of hydrochlorothiazide and to increase the release rate of the 27 
dispensed drugs. Jet dispensing was found to be a rapid technology for the preparation of multi-28 
layered films that can be used as personalized formulations for the delivery of combinations of 29 
drugs. 30 
 31 
Keywords: jet dispensing, films, combination therapy, antihypertensive drugs 32 
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1. Introduction 34 
Combination treatment has now become the standard line of treatment for cardiovascular 35 
diseases reducing the burden of morbidity and mortality associated with these pathologies [1]. 36 
Especially, for the management of hypertension, monotherapy is effective in achieving the 37 
target goal in only about 50% of patients and treatment with two or more agents from classes 38 
with different pharmacological action is often necessary to achieve adequate blood pressure 39 
control [2]. Moreover, combination therapy offers several advantages over monotherapy such 40 
as superior antihypertensive efficacy, dose strength and fewer adverse effects. For that purpose, 41 
the combination of multiple therapeutic agents into a single formulation with appropriate 42 
release profiles and doses (potentially optimized for individuals) has been suggested as an 43 
alternative approach [3]. 44 
The most recent methods for the manufacturing of multi-dosage formulations with well-defined 45 
release profiles make use of 3D printing technologies. Khaled et al. applied 3D extrusion-based 46 
printing for the manufacturing of multi-active solid dosage forms containing three [4] and five 47 
compartmentalized drugs [5] with independently controlled and well-defined release profiles 48 
indicating that printing technologies hold potential for the tailored manufacturing of medicines 49 
paving the way towards personalized care and treatment.  50 
Jet dispensing is a technology that can continuously dispense liquids with a wide range of 51 
viscosities by moving the nozzle at high speeds across the x-axis and the stage across y-axis to 52 
cover all coordinates and jetting precise volume of dots. It is a highly accurate technique and 53 
can deliver nanoquantities of drugs which cannot be achieved by the current 3D printing 54 
technology. According to this technology, the jetting device operates in a continuous mode by 55 
using a pneumatic piston with a ball tip end to push fluid through a narrow orifice at the jet 56 
nozzle tip. Air pressure is used to apply force and lifts ball-needle from its seat, thereby fluid 57 
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 4 
is allowed to flow down and around the ball-needle tip. Subsequently, the air pressure is 58 
released allowing the force from the compressed spring to slam the ball-needle tip back down 59 
into its seat, separating and ejecting a dot from the fluid. As the ball returns, the force due to 60 
acceleration breaks the stream of the drug–polymer solution, which is jetted through the nozzle. 61 
The broken stream of the solution strikes the substrate from 1.0 mm to 3.5 mm above the board 62 
forming the dot. In the field of pharmaceutics, Scoutaris et al. [6] reported the use of jet 63 
dispensing as a rapid and reproducible technology for the preparation of taste-masked mucosal 64 
thin films with drug loadings ranging from 20 to 40% and excellent content uniformity. 65 
Recently, Scoutaris et al. [7] investigated the use of jet dispensing as a high-throughput 66 
screening technology for pharmaceutical cocrystals.  67 
Hydrochlorothiazide (HCTZ) is a thiazide diuretic that works by increasing the amount of salt 68 
and water that the kidney removes from the blood causing a decrease in blood volume. It exerts 69 
its mechanism of action by inhibiting the re-absorption of salts from the renal tubules leading 70 
to increased excretion of sodium and chloride ions and consequently of water. HCTZ is 71 
employed for the treatment of oedema and hypertension. Its usual adult dose in the case of 72 
hypertension is 25 mg orally once daily that can be increased to 50 mg daily as a single or two 73 
divided doses [8]. Amiloride HCl (AMI) is a potassium-sparing diuretic which promotes 74 
excretion of sodium and chloride while retaining potassium. AMI is prescribed as adjunct 75 
therapy to thiazide or loop diuretics for the treatment of hypertension to achieve potassium 76 
conservation and thus avoid hypokalaemia. Co-administration of AMI/HCTZ 2.5/25 mg is a 77 
common fixed dose combination for the treatment of hypertension known with the non-78 
proprietary name co-amilozide. Carvedilol (CARV) is a non-selective β-blocking agent that 79 
has been approved for the treatment of heart failure, essential hypertension and coronary artery 80 
diseases. Controlled-release once-daily formulations of CARV are commercially available and 81 
considered as a more convenient option conferring an adherence benefit over immediate-82 
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release formulations in conditions traditionally prone to noncompliance such as hypertension 83 
[9]. CARV and HCTZ are often administered together as a fixed dose combination for the 84 
treatment of essential hypertension particularly in cases where monotherapy cannot provide 85 
sufficient lowering of the blood pressure [10]. A combination of more than two drugs may be 86 
required for the adequate management of blood pressure. In such cases the third agent added 87 
to the medication should belong to a different pharmacological class than the initial two drugs 88 
[11].  89 
The aim of this work is to use jet dispensing technology for the preparation of films which 90 
combine multiple drugs with different dose and independent release profiles. Two polymers 91 
(ethyl cellulose and copovidone K28) were used as substrate and hydrochlorothiazide, 92 
amiloride HCl and carvedilol as the antihypertensive agents. The films produced were 93 
characterized regarding their morphology, solid-state properties, drug-polymer interactions and 94 
distribution in each layer. The effect of the ratio of the two polymers on the in-vitro drug 95 
dissolution was also investigated. To the best of our knowledge this is the first study where the 96 
use of jet dispensing technology is extended to the preparation of films containing multiple 97 
drugs with independent release profiles.  98 
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2. Materials and methods 100 
2.1.  Materials  101 
Hydrochlorothiazide (HCTZ), carvedilol (CARV) and amiloride hydrochloride hydrate (AMI) 102 
were purchased from TCI (Tokyo Chemical Industry Ltd, UK). Ethyl cellulose (EC N10 103 
Pharm) and Kollidon® VA 64 (copovidone K28) were purchased from Hercules GmbH (USA) 104 
and BASF (Germany), respectively. The chemical structures of the antihypertensive agents and 105 
polymers used for the preparation of the films are depicted in Fig.1. Ethanol and methanol were 106 
purchased from Sigma-Aldrich (UK). All the solvent used were of analytical grade.  107 
2.2. Methods 108 
2.2.1. Preparation of films by jet dispensing 109 
According to the dosage design, the multi-layered structure of the film and the presence of the 110 
polymers will allow controlling the release of each drug. Specifically, CARV and AMI are 111 
included in the top layers of the film (layers 2 and 3) in order to achieve immediate release 112 
which will be followed by controlled release of HCTZ and CARV embedded in the polymeric 113 
matrix of the bottom layer (layer 1). A schematic diagram of the film is illustrated in Fig. 2a. 114 
Jet dispensing was carried out using a laboratory DispenseMate 583 dispenser (Nordson-115 
Asymtek, Netherlands). The layers of the films were prepared by jetting solution of the drugs 116 
and polymers in several parallel lines. For the purposes of this study, the nozzle speed and 117 
jetting rate were set at 9 mm s-1 and 33 drops s-1, respectively. The fluid pressure used was 11.4 118 
bar and the nozzle 100 μm. (Fig. 2b). The size of the ball tip and the seat was 2.4 mm and 0.32 119 
μm, respectively. For the first layer, HCTZ (7.0 mg ml-1), CARV (0.7 mg ml-1), EC (13.87 mg 120 
ml-1) and copovidone K28 (1.54 mg ml-1) were dissolved in ethanol. The same method was 121 
applied to deposit pure AMI on the surface of the first films. AMI (10 mg ml-1) was dissolved 122 
in a mixture of ethanol/water (60/40 v/v). The precursor solution leading to the formation of 123 
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the third layer consisted of CARV (30.3 mg ml-1) and copovidone K28 (60.6 mg ml-1) dissolved 124 
in methanol. Two types of formulations were prepared which differ in the ratio of 125 
EC/copovidone K28 incorporated in the first layer of the film (i.e. 90/10 and 50/50) while layer 126 
2 and 3 were common for both types of films. Table 1 summarizes the nominal composition of 127 
each layer for the two formulations of jet-dispensed films prepared in this study and the volume 128 
of the precursor solutions printed per film.  129 
2.2.2. Characterization of the films 130 
Scanning electron microscopy  131 
Scanning electron microscopy (SEM) was used to study the surface morphology of the films. 132 
Samples were placed on the holder with double-sided carbon tape and sputter-coated with gold 133 
(Edwards 188, sputter coater S1508) under argon atmosphere. SEM micrographs were taken 134 
using a Hitachi SU 8030 (Japan), at an accelerating voltage of 1.0 kV. 135 
 136 
X-ray diffraction  137 
X-ray diffraction (XRD) patterns were obtained with a Bruker D8 Advance (Germany). Cu Kα 138 
radiation at 40 mA and 40 kV with a step size of 0.02 2 theta and a speed of 0.3 s per step were 139 
used, covering a 2 theta of 5-40o. The samples were rotated at 15 rpm. For the raw materials, 140 
which were in the form of powders an exit slit of 0.2 mm was used. XRD of the films was 141 
carried out using the transmission mode with a 0.6 mm exit slit. DIFFRACplus XRD 142 
Commander was the analysis software.  143 
Differential scanning calorimetry  144 
Differential scanning calorimetry (DSC) was performed using a Mettler-Toledo 823e 145 
(Switzerland) previously calibrated with indium. Weighed powder samples (2-5 mg) were 146 
sealed in aluminium pans with a pierced lid and heated under nitrogen flow (50 ml min-1) at a 147 
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heating rate of 10 oC min-1. The heating range for the polymers and the films was from 25 to 148 
300 oC while for the raw drugs from 25 to 30 oC above the melting point.  149 
Fourier-transform infrared spectroscopy  150 
 151 
Spectra of the raw drugs, polymers and jet-dispensed (JD) films were recorded using a 152 
Spectrum100 FT-IR spectrometer (PerkinElmer, Inc., USA) equipped with the attenuated total 153 
reflection sampling accessory. Samples were scanned at room temperature, at the transmission 154 
mode, over a wavenumber range of 4000–450 cm-1, 16 accumulations and 1 cm-1 resolution. 155 
Before each measurement, a background spectrum of air was acquired under the same 156 
instrumental conditions. The acquired spectra were processed using the PerkinElmer Spectrum 157 
Express software.  158 
 159 
Confocal Raman spectroscopy 160 
Raman mapping was performed in the JD films 50/50 EC/copovidone K28 using a Jobin-Yvon 161 
LabRam 320 instrument equipped with an Olympus microscope (Horiba, Japan) by means of 162 
a He–Ne ion laser (λ = 632.8 nm) and 1800 nm-1. The experimental conditions were 100 nm 163 
slit width, a 50 × Microsoft objective and 0.2 s acquisition times. Each spectrum was the mean 164 
of two. The sample profiling was performed at step increments of 8 μm in the X–Y direction 165 
over an area of 2000 × 600 μm2. Principal component analysis (PCA) was used for analysis of 166 
the data. Prior to the analysis, all spectra were baseline corrected and normalized using the 167 
standard normal variate method (SNV) to avoid intensity deviation among the Raman spectra. 168 
The Raman chemical maps were constructed by using Solo + Mia software (Eigenvector, 169 
Research, Inc., USA). 170 
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2.2.3 Drug content and in-vitro dissolution studies 172 
 173 
Drug content analysis  174 
Jet-dispensed films were dissolved in a solution of 20% methanol in water. Solutions were 175 
filtered through a 0.45 μm PTFE syringe filters. The filtrate was analysed by HPLC-UV 176 
(Agilent 1200 Series, Agilent technologies, Germany). The stationary phase was a Waters 177 
Spherisorb® C-18 column (250 mm x 4.6 mm x 5 μm; Waters Corporation, USA). The column 178 
was maintained at 40 oC and the injection volume was 20 μl. The monitored wavelength was 179 
240 nm. For the simultaneous quantification of the three drugs, a gradient method was 180 
developed. The mobile phase consisted of the polar solvent A which was water with 1% 181 
triethanolamine (pH:2.2 adjusted by addition of orthophosphoric acid) and the organic solvent 182 
B which was acetonitrile. The flow rate was 1 ml min-1 and the gradient schedule was as 183 
follows: 0-6 min isocratic at 20% B, 6-10 min 20  70% B, 10-20 min isocratic at 70% B, 184 
followed by a linear change to initial conditions in 5 min of column re-equilibration. For each 185 
drug, the correlation coefficient of the calibration curve was R2 > 0.999 for a concentration 186 
range of 5-100 μg ml-1, indicating acceptable linearity. Drug content analysis was carried out 187 
in triplicate for each formulation (n=3).  188 
In-vitro dissolution studies 189 
The in-vitro dissolution study of the jet-dispensed films was carried out using the USP 190 
apparatus type II (Varian 705 DS, Varian Inc., USA) at 37 oC and 100 rpm stirring speed. To 191 
evaluate the dissolution of the formulations under conditions mimicking the gastrointestinal 192 
environment, jet-dispensed films were subjected to dissolution testing for 2 h in hydrochloric 193 
acid media (900 mL) at pH:1.2 and then were transferred for 3 h in phosphate buffer solution 194 
at pH:6.8. At specific time intervals up to 5 h, 5 ml of dissolution medium was withdrawn, 195 
filtered through 0.45 mm PTFE syringe filter and placed in HPLC vials for assay while 196 
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immediately replaced with 5 ml of fresh medium. The HPLC conditions for the assay were 197 
identical to those for drug content determination. Dissolution tests were made in triplicate for 198 
each formulation (n = 3).  199 
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3. Results and discussion 201 
Films of 1 cm2 were produced by jet dispensing (Fig. 3). The size of the film is close to that of 202 
a five-pence coin showing that they could be easily placed in the oral cavity and get swallowed. 203 
Jet dispensing appeared to be capable for rapid and reproducible production of thin films 204 
comprising of drugs with remarkably different water solubility in a wide dose range. Compared 205 
to the conventional method of solvent casting where a common solvent system should be 206 
selected to dissolve all drugs and polymers, in jet dispensing drug and polymer solutions in 207 
different solvents can be prepared and dispensed separately allowing greater versatility 208 
especially in the case of multi-drug films. By adjusting the film dimensions the printed drug 209 
amounts can be easily tuned and adjusted to individual patient needs [12]. Flexible 210 
manufacturing processes with adjustable dose strengths like printed films are considered 211 
particularly innovative and interesting for applications in personalized medicine or early drug 212 
development [13]. 213 
Surface morphology and solid-state characterisation 214 
SEM images reveal the multi-layered structure of the films consisting of three layers (Fig.4a, 215 
c). Layer 1 is the bottom layer consisting of HCTZ and CARV embedded in a matrix of EC 216 
and copovidone K28, layer 2 is the middle layer consisting of AMI and layer 3 is the top layer 217 
that was formed by jetting few drops of CARV in copovidone K28. Despite the differences in 218 
the ratio of polymers used for each film formulation, the respective layers of both film 219 
formulations exhibit the same morphology. Specifically, both layer 1 and 3 are smooth and 220 
transparent indicating that the drugs are incorporated in the polymeric matrix while layer 2 221 
consists of fine AMI particles (Fig. 4b). This shows that jet dispensing of drug solutions 222 
containing polymers (layer 1 and 3) simulates conventional film casting with drug embedded 223 
in the film, while in the absence of polymers (layer 2) it simulates ink-jet printing and the drug 224 
is resided on top of the film (Fig. 4d, [14])  225 
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XRD is a fast and straightforward method for determining basic information regarding the solid 226 
state of a material/ formulation with a limit of crystallinity detection in amorphous drug 227 
compositions around 5–10% [15]. The XRD diffractograms of the raw drugs exhibit 228 
characteristic peaks indicating their crystallinity while the patterns of both EC and copovidone 229 
K28 consist of an amorphous halo due to the amorphous nature of these polymers (Fig. 5a). 230 
The XRD diffractograms of the film formulations exhibit an amorphous halo with some 231 
characteristic peaks (2 theta: 16.7o, 19.5o, 19.9o, 21.5o, 24.8o, 28.3o) which are attributed to 232 
HCTZ (Fig. 5b, [16]). These results indicate that all the components of the film are in the 233 
amorphous state apart from HCTZ which is in the crystalline form. The reduced intensity of 234 
HCTZ peaks for the film 50/50 EC/copovidone K28 compared to those of the film 90/10 235 
EC/copovidone K28, indicates that increased incorporation of copovidone K28 suppressed the 236 
crystallization of HCTZ. 237 
The DSC thermographs of the raw drugs exhibit sharp endothermic peaks at 271 oC, 118 oC 238 
and 293 oC due to the melting of HCTZ, CARV and AMI, respectively (Fig. 6a). Moreover, in 239 
the case of AMI, the endothermic event from 120 to 150oC is related to the loss of water from 240 
the hydrate form of AMI. In the DSC thermographs of the jet-dispensed films, the broad 241 
endothermic peak from 40 to 100 oC can be due to the presence of copovidone K28 while the 242 
small endothermic peaks around 230-250 oC can be attributed to the melting of HCTZ (Fig. 243 
6b). The melting point of HCTZ in the films has shifted to lower temperatures due to the 244 
presence of other compounds and the reduction of the size of the drug crystals which are now 245 
embedded in the polymer matrix of the first layer forming a solid dispersion. XRD and DSC 246 
are in agreement regarding the solid state of the jet-dispensed films which are partially 247 
amorphous as all the components are in the amorphous state apart from HCTZ which retains 248 
its crystallinity in the formulation.  249 
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FT-IR 250 
FT-IR spectroscopy was implemented to identify interactions among the drugs and the 251 
polymers. The FT-IR spectra of the raw drugs, polymers and the films are illustrated in Fig. 7.  252 
To investigate the presence of interactions between copovidone K28 and CARV, films with 253 
composition corresponding to layer 3 were prepared by jet dispensing (JD CARV/Copovidone 254 
K28). The FT-IR spectrum of CARV raw material showed a well-defined characteristic peak 255 
at 3342 cm-1 corresponding to the NH stretching vibration of the secondary amine. In this 256 
region, copovidone K28 demonstrated a very broad peak due to water adsorption related to the 257 
highly hygroscopic nature of the polymer (Figs. 7a, 8a). In the FT-IR spectrum of JD 258 
CARV/Copovidone K28, the peaks assigned to NH group and water have been merged and 259 
moved towards lower wavenumber indicating hydrogen bonding interaction. Also, the 260 
broadness of the peak is attributed due to the amorphous nature of CARV [17]. Moreover, the 261 
peaks of copovidone K28 at 1667 and 1661 cm-1 which correspond to the carbonyl peaks of 262 
aliphatic and aromatic ring have moved towards lower wavenumbers at 1658 and 1652 cm-1, 263 
constituting another indication of strong hydrogen bonding interactions between CARV and 264 
copovidone K28 (Fig. 8b).  265 
 266 
The FT-IR spectra (region: 3100-3800 cm-1) of the crystalline HCTZ and the jet-dispensed 267 
films are illustrated in Fig. 9a. The most important chemical groups of HCTZ molecule are the 268 
four amino groups and the S=O groups, since these groups can interact either with other HCTZ 269 
molecules or with other compounds by means of hydrogen bonding. Specifically, HCTZ can 270 
interact with copovidone K28 via hydrogen bonding of its amino group with the carbonyl group 271 
of the polymer. HCTZ has four amino groups; two are coming from the primary sulphonamide, 272 
one from the secondary sulphonamide and finally there is one secondary amino group. In the 273 
crystalline powder, the peaks which correspond to the NH groups are at, 3392cm-1, 3359cm-1, 274 
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3262cm-1, 3166 cm-1 (Fig. 9a). The assignment of the NH peaks has been previously reported 275 
by Tajber et al. [18]. Specifically, 3392cm-1 corresponds to N-H secondary amines, 3362 cm-1 276 
3166 cm-1 at asymmetric and symmetric stretch vibration of primary sulphonamide and 277 
3262cm-1 is the N–H stretch of the secondary sulphonamide. The symmetric stretching 278 
vibration of SO groups appears at 1149cm-1 and 1163cm-1, whereas the antisymmetric 279 
stretching vibration of SO group is detected at 1347cm-1 and 1333cm-1. 280 
The potential hydrogen donors of HCTZ are the two amino groups of the primary 281 
sulphonamides, one from the secondary sulphonamide and one from a secondary amino group. 282 
In general, the best hydrogen bond donor will bond to the best hydrogen bond acceptor. 283 
Moreover, hydrogen bond donating abilities correlate with the acidities, as the more highly 284 
acidic group is a better donor among the similar functional groups. In the case of HCTZ, 285 
according to Adsmond et al. [19] the amido group is more acidic than the proton in the amino 286 
group, due to the strong electronegative character of the SO group which is able to polarize the 287 
nitrogen atom positively which in turn facilitates the release of the proton. Consequently, 288 
HCTZ will interact with the copovidone K28 via the amido group. However, the spectra did 289 
not confirm any hydrogen bonding between the carbonyl group of copovidone K28 and the 290 
amino group of HCTZ as the amino groups of HCTZ in the jet-dispensed films remain at the 291 
same position with the pure material (Fig. 9a). However, the carbonyl peaks which appeared 292 
in Fig. 9b should correspond to copovidone K28 which has moved towards lower wavenumbers 293 
at 1651 and 1657 cm-1, indicating that copovidone K28 participates in hydrogen bonding 294 
interactions probably with CARV as it was mentioned previously. This is probably due to the 295 
fact that the amino groups of CARV are more electronegative than those of HCTZ.  296 
Confocal Raman mapping 297 
The spectra of the pure compounds in the 1000 – 1650 cm-1 region are illustrated in Fig.10. 298 
Carvedilol has three characteristic peaks at 1577, 1593 and at 1633 cm-1 and one at 1286 cm-1 299 
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 15 
corresponding to CC stretching vibration and at CN sym. stretch vibration. A detailed 300 
description of the peaks has been reported by Marques et al. [20]. In HCTZ the strong peaks 301 
exist at 1295 cm-1 and at 1313 cm-1 while the strong peak at 1596 cm-1 is assigned to the NH2 302 
ending vibration. In terms of AMI, the two peaks at 1651 and at 1673 cm-1 can be attributed to 303 
C=N and C=O vibrations.  304 
In order to investigate the distribution of the drugs on the formulation the results from confocal 305 
Raman mapping technique were analysed using principal component analysis (PCA). Based 306 
on the eigenvalues, the hyperspectral data can be described by two principal components (PCs, 307 
Fig. 11a). This is a typical observation in multivariate data analysis of Raman spectra, which 308 
leads arbitrarily to the assumption that there are only two components in the system, as the first 309 
PC corresponds to the features of the strongest spectral contributors. It can be clearly observed 310 
that the three first loadings contain characteristics peak pattern of HCTZ. Hence, for instance 311 
the strong peaks at 1149cm-1 and 1163cm-1 correspond to the symmetric stretching vibration 312 
of SO groups. It is interesting also to see in PC3 the latter peak has moved towards higher 313 
wavenumbers at 1174cm-1 from 1163cm-1, probably due to interactions or due to different 314 
chemical environment of these HCTZ molecules. As in the case of HCTZ, characteristics peaks 315 
of CARV appear to all the PCs at 1287 cm-1 and at 1633cm-1, indicating that both drugs are 316 
distributed across the surface (Fig.11b). 317 
Also, the distribution of CARV in the 3rd layer was attempted. However, the PCA in the 3rd 318 
layer showed that the predominant peaks at 1288 cm-1, 1388 cm-1, 1510 cm-1 of the first PCs 319 
correspond to AMI. This can be explained by the fact that the solution of CARV/copovidone 320 
was completely absorbed by the 2nd layer.  321 
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Drug content and in-vitro dissolution studies  322 
Drug content analysis of the films produced by jet-dispensing was close to the nominal values 323 
(6% relative standard deviation or less). This can be linked to the accurate dot deposition 324 
achieved by the jet dispenser which subsequently eliminates drug loss or dose variation. 325 
Moreover, jetting of solutions rather than suspensions eliminates the risk of sedimentation prior 326 
to jetting that can adversely impact drug content in each film.  327 
The dissolution profiles of the three drugs from the two types of jet-dispensed films are 328 
illustrated in Fig. 12. For both formulations studied, complete and immediate release of AMI 329 
from the films is achieved as it expected, since it was jetted alone without any polymer in the 330 
second layer of the films. This shows that second layer manages to act as an immediate release 331 
layer following the concept of the formulation design. The release of HCTZ from the films is 332 
not complete and is delayed with the increase of EC in the polymer matrix. Unlike EC, the 333 
increase of copovidone K28 improved the release profile of all the drugs and this can be 334 
attributed to the function of this polymer as a pore former facilitating drug release from the EC 335 
matrix [21,22]. Specifically for HCTZ, when 10% of copovidone K28 was used 20% of HCTZ 336 
was released, whereas in the case of 50% of copovidone, HCTZ release increased to 60%. In 337 
the case of CARV, in both films there is an initial burst release where 20% of drug is released, 338 
attributing to the amount of drug that was deposited on the third layer and was combined with 339 
the hydrophilic copovidone K28 whereas the rest of the drug was remained trapped in the EC 340 
matrix of the first layer. The entrapment of HCTZ and CARV in the EC matrix can be attributed 341 
to the hydration of the EC and subsequent formation of a gel layer which prevents the 342 
incorporated drug molecules to migrate to the dissolution medium.  343 
4. Conclusions 344 
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Multi-layered films containing three antihypertensive drugs were prepared by jet dispensing. 345 
The films were characterized regarding their morphology and solid-state properties while FTIR 346 
spectroscopy and confocal Raman mapping provided information on the interactions between 347 
drug and polymers and the drug distribution in the layers of the films, respectively. 348 
Combinations of EC and copovidone K28 provide suitable polymeric film substrates with the 349 
ability to modify drug release. Particularly, decreased ΕC to copovidone K28 weight ratio was 350 
found to suppress the crystallization of hydrochlorothiazide and to increase the release rate of 351 
the dispensed drugs. While future studies should focus on optimising drug release from each 352 
layer, this preliminary study highlights the great potential of jet dispensing as a method capable 353 
to prepare films containing drug combinations and various modes of release (e.g. immediate 354 
and sustained drug release). Multi-layered films prepared by jet dispensing can be used as 355 
flexible formulations allowing co-delivery of drug combinations and dose personalization.  356 
Acknowledgements 357 
The authors are grateful to Ms Devyani Amin (University of Greenwich) for her help with the 358 
development of the HPLC method.  359 
Conflict of interest disclosure 360 
The authors confirm that this article has no conflict of interest.  361 
  362 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
References 363 
1. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol. Metab. Syndr. 364 
2010;2:44.  365 
2. Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based 366 
combination therapy in patients at high cardiovascular risk. Int. J. Clin. Pract. 2008. p. 781–90.  367 
3. Lafeber M, Grobbee DE, Bots ML, Thom S, Webster R, Rodgers A, et al. The Evening versus Morning Polypill 368 
Utilization Study: the TEMPUS rationale and design. Eur. J. Prev. Cardiol. [Internet]. 2014;21:425–33.  369 
4. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of tablets containing multiple drugs 370 
with defined release profiles. Int. J. Pharm. 2015;494:643–50.  371 
5. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination 372 
polypill with defined immediate and sustained release profiles. J. Control. Release. 2015;217:308–14.  373 
6. Scoutaris N, Snowden M, Douroumis D. Taste masked thin films printed by jet dispensing. Int. J. Pharm. 374 
2015;494:619–22.  375 
7. Scoutaris N, Nion A, Hurt A, Douroumis D. Jet dispensing as a high throughput method for rapid screening 376 
and manufacturing of cocrystals. CrystEngComm 2016;18:5079–82.  377 
8. Joint Formulatory Commitee. British National Formulary (BNF) 72 ed. London: BMJ Group and 378 
Pharmaceutical Press; 2016. 379 
9. Frishman WH, Henderson LS, Lukas MA. Controlled-release carvedilol in the management of systemic 380 
hypertension and myocardial dysfunction. Vasc. Health Risk Manag. 2008;1387–400.  381 
10. Langdon CG, Baxter GA, Young PH. A multicenter comparison of carvedilol with hydrochlorothiazide in the 382 
treatment of mild-to-moderate essential hypertension. J. Cardiovasc. Pharmacol. 1991;18:S51-6.  383 
11. de Cates AN, Farr MRB, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for 384 
the prevention of cardiovascular disease. Cochrane database Syst. Rev. 2014;4:CD009868.  385 
12. Alomari M, Mohamed FH, Basit AW, Gaisford S. Personalised dosing: Printing a dose of one’s own medicine. 386 
Int. J. Pharm. 2015;494:568–77.  387 
13. Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: Unmet needs and novel approaches. 388 
Int. J. Pharm. 2011;404: 1–9.  389 
14. Buanz ABM, Belaunde CC, Soutari N, Tuleu C, Gul MO, Gaisford S. Ink-jet printing versus solvent casting 390 
to prepare oral films: Effect on mechanical properties and physical stability. Int. J. Pharm. 2015;494:611–8.  391 
15. Stephenson GA, Forbes RA, Reutzel-Edens SM. Characterization of the solid state: Quantitative issues. Adv. 392 
Drug Deliv. Rev. 2001;48:67–90.  393 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
16. Pires MAS, Dos Santos RAS, Sinisterra RD. Pharmaceutical composition of hydrochlorothiazide:β-394 
cyclodextrin: Preparation by three different methods, physico-chemical characterization and in vivo diuretic 395 
activity evaluation. Molecules. 2011;16:4482–99.  396 
17. Scoutaris N, Alexander MR, Gellert PR, Roberts CJ. Inkjet printing as a novel medicine formulation technique. 397 
J. Control. Release. 2011;156:179–85.  398 
18. Tajber L, Corrigan OI, Healy AM. Physicochemical evaluation of PVP-thiazide diuretic interactions in co-399 
spray-dried composites - Analysis of glass transition composition relationships. Eur. J. Pharm. Sci. 2005;24:553–400 
63.  401 
19. Adsmond DA, Grant DJW. Hydrogen bonding in sulfonamides. J. Pharm. Sci. 2001;90:2058–77.  402 
20. Marques MPM, Oliveira PJ, Moreno AJM, Batista De Carvalho LAE. Study of carvedilol by combined Raman 403 
spectroscopy and ab initio MO calculations. J. Raman Spectrosc. 2002;33:778–83.  404 
21. Zhang X, Wang Y, Wang J, Wang Y, Li S. Effect of pore former on the properties of casted film prepared 405 
from blends of Eudragit NE 30 D and Eudragit L 30 D-55. Chem. Pharm. Bull. (Tokyo). 2007;55:1261–3.  406 
22. Yang M, Xie S, Li Q, Wang Y, Chang X, Shan L, et al. Effects of polyvinylpyrrolidone both as a binder and 407 
pore-former on the release of sparingly water-soluble topiramate from ethylcellulose coated pellets. Int. J. Pharm. 408 
2014;465:187–96.  409 
 410 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figures 
 
Fig. 1 Chemical structures of drugs and polymers used for the preparation of the multi-layered 
films by jet dispensing.  
Fig. 2 Schematic illustration of (a) the formulation’s design and (b) a jet nozzle. 
Fig. 3 Image and dimensions of a 50/50 EC/PVP multi-layered film prepared by jet dispensing. 
 
Fig. 4 SEM images of multi-layered films produced by jet dispensing.  
 
Fig. 5 XRD patterns of (a) raw drugs and polymers and (b) films prepared by jet dispensing. 
 
Fig. 6 DSC thermographs of (a) raw drugs and polymers and (b) films prepared by jet 
dispensing. 
 
Fig. 7 FT-IR spectra of (a) raw drugs and (b) polymers and films prepared by jet dispensing. 
 
Fig. 8 FT-IR spectra of carvedilol, copovidone K28 and jet-dispensed film of carvedilol-
copovidone K28 in the region of (a) 3100-3800 cm-1 and (b) 1600-1800 cm-1. 
 
Fig. 9 FT-IR spectra of hydrochlorothiazide, copovidone K28 and jet-dispensed films in the 
region of (a) 3100-3800 cm-1 and (b) 1600-1800 cm-1.  
Fig. 10 Raman spectra of the raw drugs in the 1000-1650 cm-1 region. 
 
Fig. 11 (a) Principal components (PCs) versus eigenvalues and (b) principal component 
analysis (PCA) of confocal Raman spectra for the JD 50/50 EC/copovidone K28 film 
formulation (red and brown arrows correspond to peaks of HCTZ and CARV, respectively). 
 
Fig. 12 In-vitro dissolution profiles of the three drugs from multi-layered jet-dispensed films 
with different EC/copovidone K28.  
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Fig. 3 Image and dimensions of a 50/50 EC/PVP multi-layered film prepared by jet dispensing. 
  
 
 
Fig. 4 SEM images of multi-layered films produced by jet dispensing.  
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Fig. 5 XRD patterns of (a) raw drugs and polymers and (b) films prepared by jet dispensing. 
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Fig. 6 DSC thermographs of (a) raw drugs and polymers and (b) films prepared by jet dispensing. 
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Fig. 7 FT-IR spectra of (a) raw drugs and (b) polymers and films prepared by jet dispensing. 
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Fig. 8 FT-IR spectra of carvedilol, copovidone K28 and jet-dispensed film of carvedilol-copovidone K28 in the 
region of (a) 3100-3800 cm-1 and (b) 1600-1800 cm-1. 
  
 
 
Fig. 9 FT-IR spectra of hydrochlorothiazide, copovidone K28 and jet-dispensed films in the region of (a) 3100-
3800 cm-1 and (b) 1600-1800 cm-1.  
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Fig. 10 Raman spectra of the raw drugs in the 1000-1650 cm-1 region. 
  
 
 
Fig. 11 (a) Principal components (PCs) versus eigenvalues and (b) principal component analysis (PCA) of 
confocal Raman spectra for the JD 50/50 EC/copovidone K28 film formulation (red and brown arrows correspond 
to peaks of HCTZ and CARV, respectively).  
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Fig. 12 In-vitro dissolution profiles of the three drugs from multi-layered jet-dispensed films with different 
EC/copovidone K28.  
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Table 
 
Table 1. Nominal composition of each layer for the jet-dispensed film formulations and volume of the precursor 
solutions printed per film.  
 
Film 
HCTZ 
(mg) 
CARV 
(mg) 
AMI 
(mg) 
EC 
(mg) 
Copovidone 
K28 (mg) 
Volume 
printed 
per film 
(ml) 
Layer 1 90/10 25 2.5 - 49.5 5.5 3.57 
 50/50 25 2.5 - 27.5 27.5 3.57 
Layer 2  - - 2.5 - - 0.25 
Layer 3  - 1 - - 2 0.033 
 
Table
